Tranexamic Acid interactions

Conditions

Conditions in which Tranexamic Acid needs care, as documented in this source.

• Disseminated Intravascular Coagulation

  Major

  The use of tranexamic acid is contraindicated in patients with active intravascular clotting.

  1 source

  1. "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc (2022):

• Subarachnoid Hemorrhage

  Major

  The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage. Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.

  1 source

  1. "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn (2001):

• Color Vision Defects

  Moderate

  Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances. Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy. Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted. Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months. Discontinue treatment if changes in ophthalmological examination occur.

  1 source

  1. "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn (2001):

• Kidney Diseases

  Moderate

  Tranexamic acid is primarily eliminated by the kidney. Approximately 95% of tranexamic acid is excreted in the urine unchanged. The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment. Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function. Clinical monitoring of renal and clotting functions is recommended.

  1 source

  1. "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn (2001):

• Seizures

  Moderate

  Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system. Caution is advised if administering in patients with convulsive disorders.

  1 source

  1. "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc (2022):